Aminothiazole inhibitors of cyclin dependent kinases
US6040321A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 21, 1998 |
| Grant date | Mar 21, 2000 |
| Priority date | — |
| Expiry date | Oct 21, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings: PA1 R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl; PA1 R.sub.3 is aryl or heteroaryl PA1 R.sub.4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CONH-alkyl, COO-alkyl, SO.sub.2 -alkyl, C(NCN)NH-alkyl, C(NNO.sub.2)NH-alkyl, C(NH)NH-alkyl, C(NH)NHCO-alkyl, C(NOR.sub.6)NH-alkyl, PA1 R.sub.5 is hydrogen or alkyl; PA1 R.sub.6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; PA1 m is an integer of 0 to 2; and PA1 n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.